Keywords: pfizer, sanofi, discontinue, cb1, obesity, drugs, once

Pfizer and Sanofi discontinue CB1 obesity drugs

Article | 10 November 2008

Print This

A once promising class of obesity drugs - the cannabinoid receptor-1 blockers - has been dealt a huge blow after ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in